PDX model details
| PDX ID |
394M |
| Host Strain(and Source) |
NSG Source: Monash University |
| Host Strain Immune system Humanized |
NO |
| Host Type |
Testosterone supplemented |
| Graft Site |
Subcutaneous |
Current Generation (* indicates number of generations grown in Castrate host) |
9 |
| Average PDX Generation Time (days +/- SEM) |
96 ± 11 |
| Tumour preparation |
Tumor solid |
| Tumour Characterization Technology |
Histology, IHC, STR profiling, targeted DNA sequencing, RNAseq |
| Tumour confirmed not to be of Mouse/EBV origin |
Yes; negative for CD45 and/or positive for human CK8/18 and/or human mitochondria by IHC |
| Passage QA performed |
Routine QA every 2-3 passages |
| Associated meta data |
| PDX model availability |
Yes (fixed, frozen) |
| Governance restriction for distribution |
Available to investigators with appropriate ethics approvals, approved EOI from MURAL committee, and material transfer agreements |
| Pubmed ID |
34413304 |
| |
|
| Markers |
394M |
| AR |
Y |
| PSA |
Y |
| PSMA |
Y |
| NE |
N |
| ERG |
N |
This heatmap displays the call type of curated CNVs in the presented samples.
This heatmap displays the call type of CNVs in commonly occurred samples.
This table displays curated CNVs
|
PDX ID
|
Gene Symbol
|
CNV Log2
|
CNV Copy
|
CNV Call
|
Experiments name
|
Platform
|
Reference genome
|
| 394M |
PIK3CB |
0.846714 |
3.5968 |
gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 394M |
PIK3CA |
1.12939 |
4.37532 |
gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 394M |
MET |
0.498595 |
2.82567 |
gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 394M |
CHD7 |
1.21014 |
4.6272 |
gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 394M |
CHD7 |
1.34785 |
5.09065 |
gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 394M |
CHD7 |
1.17729 |
4.52303 |
gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 394M |
MRE11A |
0.645656 |
3.1289 |
gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 394M |
USP28 |
0.50684 |
2.84187 |
gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 394M |
KMT2A |
0.890831 |
3.70849 |
gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 394M |
STAB2 |
0.580019 |
2.98974 |
gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 394M |
AR |
2.56388 |
5.91296 |
gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 394M |
AR |
2.12994 |
4.37699 |
gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 394M |
PTEN |
-0.793542 |
1.15385 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 394M |
SUFU |
-0.793542 |
1.15385 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 394M |
CDKN1B |
-0.851785 |
1.1082 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 394M |
RB1 |
-1.35882 |
0.779802 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 394M |
USP7 |
-0.742396 |
1.19549 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 394M |
PALB2 |
-0.862553 |
1.09996 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 394M |
CDH1 |
-0.807688 |
1.14259 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 394M |
FANCA |
-0.760374 |
1.18069 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 394M |
PRPF8 |
-0.798118 |
1.1502 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 394M |
TP53 |
-0.798118 |
1.1502 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 394M |
CHD1 |
-21.7261 |
0.000000577 |
homdel
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 394M |
CHD1 |
-9.11739 |
0.00360099 |
homdel
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 394M |
PTEN |
-6.12376 |
0.028681 |
homdel
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
Clinical Information
| Sample Number |
394M |
| Sample Site |
Liver |
| Sample source |
Biopsy |
| Pathology Tumour Diagnosis |
None |
| Gleason Score |
None |
| Primary Gleason Score |
None |
| Secondary Gleason Score |
None |
| Tertiary Gleason Score |
None |
| ISUP Grade Group |
|
| Tumour Grade |
|
| D'Amico Risk Classification |
|
| Tumour Volume (in cc) |
0.0 |
| Treatment Prior to Specimen Collection |
ADT, docetaxel, cabazitaxel, enzalutamide, navelbine |
| |
|
Patient Information
| Patient Number |
394 |
| Sex |
Male |
| Diagnosis |
Prostate Cancer |
| PSA at diagnosis (ng/mL) |
NA |
| Consent to share data |
|
| |
|
This heatmap displays the mutations of curated sequence variants.
Download
This table displays curated sequence variants
|
PDX ID
|
Gene Symbol
|
Depth
|
ALT_FREQ
|
Consequence
|
Exon
|
GnomAD_AF
|
CADD_PHRED
|
Clinvar_clnsig
|
Platform
|
Experiments Name
|
Reference
|
Library Type
|
Instrument Type
|
| 394M |
TP53 |
206 |
1.0 |
missense_variant |
'7/11 |
0 |
28.8 |
Pathogenic
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 394M |
CDKN1B |
195 |
0.92 |
frameshift_variant |
'1/3 |
. |
. |
-
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 394M |
GRIN2A |
273 |
0.45 |
missense_variant |
'4/14 |
. |
26.1 |
-
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 394M |
SPOP |
503 |
0.42 |
inframe_deletion |
'7/12 |
. |
. |
-
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
No information in Drug dosing Table